Innoviva Inc. Stock
Innoviva Inc. Stock
There is no change in the price for Innoviva Inc. today.
Innoviva Inc. is currently one of the favorites of our community with 10 Buy predictions and no Sell predictions.
As a result the target price of 36 € shows a very positive potential of 98.9% compared to the current price of 18.1 € for Innoviva Inc..
Pros and Cons of Innoviva Inc. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Innoviva Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Innoviva Inc. | 0.000% | -3.209% | -6.701% | 13.836% | 10.366% | 53.390% | 44.800% |
| Pacira Pharmaceuticals | 0.000% | -1.724% | 2.703% | 21.925% | 5.556% | -34.483% | -54.400% |
| Corcept Therapeutics Inc. | 0.260% | 22.242% | 25.500% | 64.219% | 43.229% | 242.448% | 438.132% |
| Supernus Pharmaceuticals | 0.000% | -3.500% | -7.656% | 26.974% | -10.233% | 33.103% | 70.796% |
Comments
Innoviva (INVA) had its "buy" rating reaffirmed by BTIG Research. They now have a $42.00 price target on the stock.
Show more
Ratings data for INVA provided by MarketBeat
Innoviva (INVA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $46.00 price target on the stock.
Show more
Ratings data for INVA provided by MarketBeat
Innoviva (INVA) had its "buy" rating reaffirmed by BTIG Research. They now have a $42.00 price target on the stock.
Show more
Ratings data for INVA provided by MarketBeat
News
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
Dauntless Investment Group disclosed in a May 14, 2026, SEC filing that it bought 116,863 shares of Innoviva (NASDAQ:INVA), an estimated $2.52 million trade based on quarterly average pricing.
